{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:13:04Z","timestamp":1774627984995,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13318-026-00990-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:33:25Z","timestamp":1773412405000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-0195","authenticated-orcid":false,"given":"Luigi Francesco","family":"Iannone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Papetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Toldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Valeriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"19","key":"990_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"issue":"9","key":"990_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102409355601","volume":"30","author":"TW Victor","year":"2010","unstructured":"Victor TW, et al. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065\u201372.","journal-title":"Cephalalgia"},{"issue":"2","key":"990_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ncl.2008.11.003","volume":"27","author":"DW Lewis","year":"2009","unstructured":"Lewis DW. Pediatric migraine. Neurol Clin. 2009;27(2):481\u2013501.","journal-title":"Neurol Clin"},{"issue":"1","key":"990_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10194-010-0256-6","volume":"12","author":"C Termine","year":"2011","unstructured":"Termine C, et al. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. J Headache Pain. 2011;12(1):25\u201334.","journal-title":"J Headache Pain"},{"issue":"10","key":"990_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737175.2020.1797493","volume":"20","author":"R Rao","year":"2020","unstructured":"Rao R, Hershey AD. An update on acute and preventive treatments for migraine in children and adolescents. Expert Rev Neurother. 2020;20(10):1017\u201327.","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"990_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/WNL.0000000000008105","volume":"93","author":"M Oskoui","year":"2019","unstructured":"Oskoui M, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500\u20139.","journal-title":"Neurology"},{"issue":"3","key":"990_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamapediatrics.2013.508","volume":"167","author":"K El-Chammas","year":"2013","unstructured":"El-Chammas K, et al. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr. 2013;167(3):250\u20138.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"990_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa1610384","volume":"376","author":"SW Powers","year":"2017","unstructured":"Powers SW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"990_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11916-022-01047-5","volume":"26","author":"S Evers","year":"2022","unstructured":"Evers S. CGRP in childhood and adolescence migraine: (patho)physiological and clinical aspects. Curr Pain Headache Rep. 2022;26(6):475\u201380.","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"990_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565\u2013644.","journal-title":"Physiol Rev"},{"issue":"10483","key":"990_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, et al. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405(10483):1014\u201326.","journal-title":"Lancet"},{"key":"990_CR12","unstructured":"Teva Pharmaceutical Inc. FDA Approves Expanded Indication for AJOVY\u00ae (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine. 2025 [cited 2025 27 Aug 2025]; Available from: https:\/\/ir.tevapharm.com\/news-and-events\/press-releases\/press-release-details\/2025\/FDA-Approves-Expanded-Indication-for-AJOVY-fremanezumab-vfrm-The-First-Anti-CGRP-Preventive-Treatment-for-Pediatric-Episodic-Migraine\/default.aspx."},{"issue":"3","key":"990_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2504546","volume":"394","author":"AD Hershey","year":"2026","unstructured":"Hershey AD, et al. Fremanezumab in children and adolescents with episodic migraine. N Engl J Med. 2026;394(3):243\u201352.","journal-title":"N Engl J Med"},{"key":"990_CR14","unstructured":"Teva Pharmaceutical Inc. A study to test if fremanezumab is effective in preventing episodic migraine in patients 6 to 17 years of age. 2020, https:\/\/ClinicalTrials.gov\/show\/NCT04458857."},{"key":"990_CR15","doi-asserted-by":"crossref","unstructured":"Hershey A, et al. Efficacy and safety of fremanezumab for the preventive treatment of episodic migraine in children and adolescents: a phase 3, randomized, double-blind, placebo-controlled study (PL5.001). Neurology, 2025. 104.","DOI":"10.1212\/WNL.0000000000211143"},{"issue":"2","key":"990_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, et al. Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review. Headache. 2025;65(2):342\u201352.","journal-title":"Headache"},{"issue":"10","key":"990_CR17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/03331024211007789","volume":"41","author":"O Cohen-Barak","year":"2021","unstructured":"Cohen-Barak O, et al. Dose selection for Fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia. 2021;41(10):1065\u201374.","journal-title":"Cephalalgia"},{"key":"990_CR18","unstructured":"Teva Pharmaceutical Inc. Fremanezumab compassionate use program for pediatric patients (NCT03539393). 2025 [cited 2025 27 Aug 2025]."},{"key":"990_CR19","unstructured":"Clinicaltrial.gov. A study to test if fremanezumab is effective in preventing chronic migraine in patients 6 to 17 years of age. 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04464707."},{"key":"990_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/life12040536","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Cesaris F, Geppetti P. Emerging pharmacological treatments for migraine in the pediatric population. Life Basel. 2022. https:\/\/doi.org\/10.3390\/life12040536.","journal-title":"Life Basel"},{"key":"990_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512268","author":"M Silvestro","year":"2023","unstructured":"Silvestro M, et al. Migraine treatment: towards new pharmacological targets. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241512268.","journal-title":"Int J Mol Sci"},{"key":"990_CR22","unstructured":"Teva Pharmaceutical Inc, Fremaneuzumab FDA prescribing information. 2025."},{"issue":"10","key":"990_CR23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/head.13414","volume":"58","author":"CL Szperka","year":"2018","unstructured":"Szperka CL, et al. Recommendations on the use of Anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018;58(10):1658\u201369.","journal-title":"Headache"},{"issue":"1","key":"990_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, et al. Blocking CGRP in migraine patients\u2014A review of pros and cons. J Headache Pain. 2017;18(1):96\u201396.","journal-title":"J Headache Pain"},{"key":"990_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.pediatrneurol.2024.05.013","volume":"157","author":"L Moore","year":"2024","unstructured":"Moore L, Pakalnis A. Calcitonin gene-related peptide inhibitors in the treatment of migraine in the pediatric and adolescent populations: a review. Pediatr Neurol. 2024;157:87\u201395.","journal-title":"Pediatr Neurol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-00990-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:23:51Z","timestamp":1774625031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-00990-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-00990-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LFI received financial support, consulting fees for the participation in advisory boards and support for attending meetings from: Teva, Eli Lilly, Lundbeck, Pfizer, Organon and AbbVie; he is associate editor for the\n                      Frontiers in Neurology\n                      Headache and Neurogenic Pain section and junior editor in\n                      Cephalalgia and Cephalalgia\n                      report. MV received honoraries for talks and papers and consulting fees for the participation in advisory boards from: Teva, Pfizer, Lusofarmaco, and Biogen; he is chief editor of\n                      Pain Research and Management\n                      , associate editor for the\n                      Frontiers in Neurology\n                      Headache and Neurogenic Pain section,\n                      Journal of Clinical Medicine, Life, Brain Sciences\n                      , and\n                      BMC Neurology\n                      ; he is in the Editorial Board of\n                      Journal of Headache and Pain\n                      ,\n                      European Journal of Pain\n                      ,\n                      Clinical Neurophysiology\n                      , and\n                      Neurological Sciences\n                      . LP is a member of the junior editorial board of\n                      The Journal of Headache and Pain\n                      , section board member for Children in the area of\n                      Pediatric Neurology and Neurodevelopmental Disorders\n                      , editorial board member of\n                      Confinia Cephalalgica\n                      , and associate editor for the Pediatric Neurology section of\n                      Frontiers in Neurology\n                      . She has received financial support from TEVA, Eli Lilly, Lundbeck, Pfizer, AbbVie, and Epitech for the organization of scientific meetings and support from attending meetings from MERCK and Biogen. IT is a member of editorial board of of\n                      Headache\n                      ; Review Editor of\n                      Frontiers (Epilepsy, Neurogenomics, Pediatric Cardiology, Pediatric Neurology)\n                      ; Co-Associate Editors of\n                      Perspectives in Pediatric Neurology\n                      . She has received financial support for the organization of scientific meetings and support for attending meetings from: UCB, JAZZ-Pharmaceuticals, and Italfarmaco. The other Authors have no conflict of interest related to the topic of the review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}